Dermatology experts speaking at Fall Clinical Derm 2026 called for earlier use of Janus kinase (JAK) inhibitors in atopic dermatitis (AD) and vitiligo, arguing that clinicians defer the drug class too long in both diseases.

The recommendation, reported by Managed Healthcare Executive from the conference, positions JAK inhibitors as an option clinicians should reach for before disease becomes chronic, refractory and harder to reverse — particularly in vitiligo, where repigmentation potential declines as depigmented patches mature.

Why does timing matter in vitiligo?

Vitiligo has long lacked systemic options with meaningful efficacy. Topical corticosteroids and calcineurin inhibitors help localized disease, but widespread or rapidly progressive vitiligo often escapes control. JAK inhibitors intervene in the interferon-γ/ CXCL10 axis that drives melanocyte destruction, and the experts at the meeting framed early intervention as the window in which melanocytes may still be recoverable.

The panel's argument rests on disease biology: once follicular melanocyte reservoirs are exhausted, even effective systemic therapy cannot restore pigment. Delay, in this framing, is not neutral — it is actively harmful to long-term outcomes.

What about atopic dermatitis?

In atopic dermatitis, the case for earlier JAK use runs on different logic. Clinicians typically sequence topical agents, phototherapy, and biologic therapy before oral JAK inhibitors, reserving the class for patients who fail multiple lines. The Fall Clinical Derm faculty challenged that sequencing.

JAK inhibitors offer oral administration, rapid symptom relief and activity across multiple cytokine pathways relevant to AD, including IL-4, IL-13 and IL-31 signaling. For patients with severe pruritus or barriers to biologic access, the experts argued, waiting through successive treatment failures prolongs suffering and may deepen the chronic inflammatory phenotype.

What stands in the way?

Class labeling remains the central obstacle. JAK inhibitors in dermatology carry boxed warnings shared with the older tofacitinib rheumatology data — covering major adverse cardiovascular events, malignancy, thrombosis, serious infections and mortality. Payers also impose step therapy and prior authorization requirements that push the class to later lines regardless of clinician judgment.

The Fall Clinical Derm panel's message directly contests that default. Their position: clinicians should weigh the class on its own dermatology-trial safety record and patient-specific risk, rather than defaulting to late-line use driven by label caution and payer policy.

Managed Healthcare Executive's coverage of the session reflects a broader conversation in the field as the roster of approved dermatology JAK agents grows and real-world experience accumulates. How quickly treatment guidelines, payers and prescribers translate the "earlier is better" argument into practice will shape outcomes in both diseases over the coming years.